Effective and Safe Stimulation of Humoral and Cell-Mediated Immunity by Intradermal Immunization with a Cyclic Dinucleotide/Nanoparticle Combination Adjuvant

2020 ◽  
pp. ji2000703
Author(s):  
Juan F. Hernandez-Franco ◽  
Yung-Yi C. Mosley ◽  
Jackeline Franco ◽  
Darryl Ragland ◽  
Yuan Yao ◽  
...  

Pteridines ◽  
1990 ◽  
Vol 2 (1) ◽  
pp. 51-57
Author(s):  
Arnaldo Caruso ◽  
Maria de Francesco ◽  
Rosanna Gonzales ◽  
Patrizia Pollara ◽  
Lorenzo Zanoni ◽  
...  

Summary Activated cell-mediated immunity, as defined by four markers, has been studied in HIV-infected patients, and compared with the clinical stages of HIV infection. All the values obtained with such markers (interferon-y expressed on lymphocytes, soluble CD8, soluble IL-2 receptor, and serum neopterin) were observed to increase with the progressive stages of HIV infection, with the highest figures occurring in stage IV-C patients. Since the replication of HIV depend strictly on the stimulation of infected cells, T-cell activation in vitro might contribute to a further spread of HIV-1 in infected subjects. Thus permanent or multiple stimulation of the cellular immune system could be an important cofactor in the progression of this syndrome.



1980 ◽  
Vol 29 (3) ◽  
pp. 873-878
Author(s):  
A Bellahsène ◽  
A Forsgren

The effect of fusidic acid on the immune response in mice was studied. At the nontoxic dose of 500 mg/kg per day, the cell-mediated immunity was strongly inhibited. A marked and significant prolonged survival of split-heart allografts in treated animals was detected. The survival time of allografts in mice receiving fusidic acid from the day of the transplantation until the grafts were rejected was 26.1 days compared with 14.5 days in untreated animals. In mice treated also before the transplantation, the mean survival of the allografts were even longer. The phytohemagglutinin response, as well as the mixed lymphocyte culture stimulation of spleen lymphocytes from mice given 500 mg of fusidic acid per kg daily for 1 week, were significantly inhibited. At the same dose there was also a significantly decreased primary antibody response to sheep erythrocytes, but it was of limited biological significance. The immunosuppressive effect in animals treated with a human therapeutic dose of fusidic acid (25 mg/kg per day) was less pronounced but significant. The relevance of these results is discussed.



1996 ◽  
Vol 18 (5) ◽  
pp. 295-303 ◽  
Author(s):  
Hwan Mook Kim ◽  
Sang Bae Han ◽  
Goo Taeg Oh ◽  
Young Hee Kim ◽  
Dong Ho Hong ◽  
...  


1988 ◽  
Vol 8 (2) ◽  
pp. 201-207 ◽  
Author(s):  
Daila S. Gridley ◽  
Terry D. Shultz ◽  
Dwight R. Stickney ◽  
James M. Slater


2018 ◽  
Vol 37 (3) ◽  
pp. 49-57 ◽  
Author(s):  
Takamitsu TSUKAHARA ◽  
Shin-ichi NAKAMURA ◽  
Gustavo A. ROMERO-PÈREZ ◽  
Makoto OHWAKI ◽  
Takaharu YANAGISAWA ◽  
...  


1985 ◽  
Vol 63 (19) ◽  
pp. 1009-1018 ◽  
Author(s):  
J. A. R. Smith ◽  
W. S. Hendry ◽  
J. L. Duncan ◽  
J. N. Norman


2021 ◽  
Vol 12 ◽  
Author(s):  
Erandi Velarde de la Cruz ◽  
Lingyun Wang ◽  
Deepanwita Bose ◽  
Sailaja Gangadhara ◽  
Robert L. Wilson ◽  
...  

We modified a Sabin Oral Poliovirus Vaccine (OPV) vector to permit secretion of the antigens of interest with the goal of improving anti-HIV Env humoral responses in a SHIV mucosal immunization composed of DNA and recombinant OPVs. We evaluated stimulation of systemic and mucosal cell-mediated and humoral immunity in Rhesus macaques by two regimens, both involving a prime with a SHIVBG505 DNA construct producing non-infectious particles formulated in lipid nanoparticles, administered in the oral cavity, and two different viral vector boostings, administered in the oral cavity and intestinally. Group 1 was boosted with rMVA-SHIVBG505, expressing SIV Gag/Pol and HIVBG505 Env. Group 2 was boosted with a SHIVBG505-OPV vaccine including a non-secreting SIVmac239CA-p6-OPV, expressing Gag CA, NC and p6 proteins, and a HIVBG505C1-V2-OPV, secreting the C1-V2 fragment of HIV EnvBG505, recognized by the broadly neutralizing antibody PG16. A time course analysis of anti-SHIV Gag and Env CD4+ and CD8+ T-cell responses in PBMC and in lymph node, rectal, and vaginal MNC was carried out. Both regimens stimulated significant cell-mediated responses in all compartments, with SHIVBG505-OPV immunization stimulating more significant levels of responses than rMVA- SHIVBG505. Boolean analysis of these responses revealed predominantly monofunctional responses with multifunctional responses also present in all tissues. Stimulation of antibody responses was disappointing in both groups with negative anti-SHIV IgG in plasma, and IgA in salivary, rectal and vaginal secretions being restricted to a few animals. After repeated rectal challenge with SHIVBG505, two Group 1 animals remained uninfected at challenge termination. No significant differences were observed in post-infection viral loads between groups. After the acute phase decline, CD4+ T cell percentages returned to normal levels in vaccinated as well as control animals. However, when compared to controls, vaccinate groups had more significant preservation of PBMC and rectal MNC Th17/Treg ratios, considered the strongest surrogate marker of progression to AIDS. We conclude that the vaccine platforms used in this study are insufficient to stimulate significant humoral immunity at the tested doses and schedule but sufficient to stimulate significant mucosal and systemic cell-mediated immunity, impacting the preservation of key Th17 CD4+ T cells in blood and rectal mucosa.







Sign in / Sign up

Export Citation Format

Share Document